Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Image credit: Medical Sciences Division and John Cairns


John Radcliffe Hospital, Level 6, Headley Way, Headington, Oxford, OX3 9DU

Amy Cross

MSc, PhD

Postdoctoral Scientist

Transplantation is the best option for many patients with end-stage organ failure, however this is undermined by the capacity of the body to recognise tissues from genetically different individuals and reject the transplant. Rejection damages the transplant and reduces the graft function, taking us back to square one. 

To tackle rejection, the Transplantation Research and Immunology Group (TRIG) are investigating the effectiveness of regulatory T cell (Treg) transfer therapies in renal transplantation. My research aims to continue the optimisation of Treg-based therapies. I will explore the impact of low dose IL-2 on human regulatory T cells in models of solid organ and bone marrow transplantation.   

This work is being generously supported by the Oxford-Celgene Fellowship. The support of Celgene will provide useful insight and help to advance this translational research.